BACKGROUND & AIMS: Imaging tests can identify patients with pancreatic neoplastic cysts but not microscopic dysplasia. We investigated whether mutant TP53 can be detected in duodenal samples of secretin-stimulated pancreatic juice, and whether this assay can be used to screen for high-grade dysplasia and invasive pancreatic cancer. METHODS: We determined the prevalence of mutant TP53 in microdissected pancreatic intraepithelial neoplasias (PanINs), intraductal papillary mucinous neoplasms (IPMNs), and invasive adenocarcinomas. TP53 mutations were quantified by digital high-resolution melt-curve analysis and sequencing of secretin-stimulated pancreatic juice samples, collected from duodena of 180 subjects enrolled in Cancer of the Pancreas Screening trials; patients were enrolled because of familial and/or inherited predisposition to pancreatic cancer, or as controls. RESULTS: TP53 mutations were identified in 9.1% of intermediate-grade IPMNs (2 of 22), 17.8% of PanIN-2 (8 of 45), 38.1% of high-grade IPMNs (8 of 21), 47.6% of PanIN-3 (10 of 21), and 75% of invasive pancreatic adenocarcinomas (15 of 20); no TP53 mutations were found in PanIN-1 lesions or low-grade IPMNs. TP53 mutations were detected in duodenal samples of pancreatic juice from 29 of 43 patients with pancreatic ductal adenocarcinoma (67.4% sensitivity; 95% confidence interval, 0.52-0.80) and 4 of 8 patients with high-grade lesions (PanIN-3 and high-grade IPMN). No TP53 mutations were identified in samples from 58 controls or 55 screened individuals without evidence of advanced lesions. CONCLUSIONS: We detected mutant TP53 in secretin-stimulated pancreatic juice samples collected from duodena of patients with high-grade dysplasia or invasive pancreatic cancer. Tests for mutant TP53 might be developed to improve the diagnosis of and screening for pancreatic cancer and high-grade dysplasia. Clinical Trial numbers: NCT00438906 and NCT00714701.
BACKGROUND & AIMS: Imaging tests can identify patients with pancreatic neoplastic cysts but not microscopic dysplasia. We investigated whether mutant TP53 can be detected in duodenal samples of secretin-stimulated pancreatic juice, and whether this assay can be used to screen for high-grade dysplasia and invasive pancreatic cancer. METHODS: We determined the prevalence of mutant TP53 in microdissected pancreatic intraepithelial neoplasias (PanINs), intraductal papillary mucinous neoplasms (IPMNs), and invasive adenocarcinomas. TP53 mutations were quantified by digital high-resolution melt-curve analysis and sequencing of secretin-stimulated pancreatic juice samples, collected from duodena of 180 subjects enrolled in Cancer of the Pancreas Screening trials; patients were enrolled because of familial and/or inherited predisposition to pancreatic cancer, or as controls. RESULTS:TP53 mutations were identified in 9.1% of intermediate-grade IPMNs (2 of 22), 17.8% of PanIN-2 (8 of 45), 38.1% of high-grade IPMNs (8 of 21), 47.6% of PanIN-3 (10 of 21), and 75% of invasive pancreatic adenocarcinomas (15 of 20); no TP53 mutations were found in PanIN-1 lesions or low-grade IPMNs. TP53 mutations were detected in duodenal samples of pancreatic juice from 29 of 43 patients with pancreatic ductal adenocarcinoma (67.4% sensitivity; 95% confidence interval, 0.52-0.80) and 4 of 8 patients with high-grade lesions (PanIN-3 and high-grade IPMN). No TP53 mutations were identified in samples from 58 controls or 55 screened individuals without evidence of advanced lesions. CONCLUSIONS: We detected mutant TP53 in secretin-stimulated pancreatic juice samples collected from duodena of patients with high-grade dysplasia or invasive pancreatic cancer. Tests for mutant TP53 might be developed to improve the diagnosis of and screening for pancreatic cancer and high-grade dysplasia. Clinical Trial numbers: NCT00438906 and NCT00714701.
Authors: Elizabeth C Verna; Caroline Hwang; Peter D Stevens; Heidrun Rotterdam; Stavros N Stavropoulos; Carolyn D Sy; Martin A Prince; Wendy K Chung; Robert L Fine; John A Chabot; Harold Frucht Journal: Clin Cancer Res Date: 2010-09-28 Impact factor: 12.531
Authors: Kieran Brune; Tadayoshi Abe; Marcia Canto; Lauren O'Malley; Alison P Klein; Anirban Maitra; N Volkan Adsay; Elliot K Fishman; John L Cameron; Charles J Yeo; Scott E Kern; Michael Goggins; Ralph H Hruban Journal: Am J Surg Pathol Date: 2006-09 Impact factor: 6.394
Authors: Chanjuan Shi; Alison P Klein; Michael Goggins; Anirban Maitra; Marcia Canto; Syed Ali; Richard Schulick; Emily Palmisano; Ralph H Hruban Journal: Clin Cancer Res Date: 2009-12-15 Impact factor: 12.531
Authors: J W Poley; I Kluijt; D J Gouma; F Harinck; A Wagner; C Aalfs; C H J van Eijck; A Cats; E J Kuipers; Y Nio; P Fockens; M J Bruno Journal: Am J Gastroenterol Date: 2009-06-02 Impact factor: 10.864
Authors: P Langer; P H Kann; V Fendrich; N Habbe; M Schneider; M Sina; E P Slater; J T Heverhagen; T M Gress; M Rothmund; D K Bartsch Journal: Gut Date: 2009-05-25 Impact factor: 23.059
Authors: Masaya Suenaga; Jun Yu; Koji Shindo; Koji Tamura; Jose Alejandro Almario; Christopher Zaykoski; P Dane Witmer; Shahriar Fesharakizadeh; Michael Borges; Anne-Marie Lennon; Eun-Ji Shin; Marcia Irene Canto; Michael Goggins Journal: Clin Cancer Res Date: 2018-01-04 Impact factor: 12.531
Authors: Waki Hosoda; Peter Chianchiano; James F Griffin; Meredith E Pittman; Lodewijk Aa Brosens; Michaël Noë; Jun Yu; Koji Shindo; Masaya Suenaga; Neda Rezaee; Raluca Yonescu; Yi Ning; Jorge Albores-Saavedra; Naohiko Yoshizawa; Kenichi Harada; Akihiko Yoshizawa; Keiji Hanada; Shuji Yonehara; Michio Shimizu; Takeshi Uehara; Jaswinder S Samra; Anthony J Gill; Christopher L Wolfgang; Michael G Goggins; Ralph H Hruban; Laura D Wood Journal: J Pathol Date: 2017-03-30 Impact factor: 7.996
Authors: Hanno Matthaei; Jian Wu; Marco Dal Molin; Chanjuan Shi; Sven Perner; Glen Kristiansen; Philipp Lingohr; Jörg C Kalff; Christopher L Wolfgang; Kenneth W Kinzler; Bert Vogelstein; Anirban Maitra; Ralph H Hruban Journal: Am J Surg Pathol Date: 2014-03 Impact factor: 6.394
Authors: James R Eshleman; Alexis L Norris; Yoshihiko Sadakari; Marija Debeljak; Michael Borges; Colleen Harrington; Elaine Lin; Aaron Brant; Thomas Barkley; J Alejandro Almario; Mark Topazian; James Farrell; Sapna Syngal; Jeffrey H Lee; Jun Yu; Ralph H Hruban; Mitsuro Kanda; Marcia Irene Canto; Michael Goggins Journal: Clin Gastroenterol Hepatol Date: 2014-12-04 Impact factor: 11.382
Authors: Simeon Springer; Yuxuan Wang; Marco Dal Molin; David L Masica; Yuchen Jiao; Isaac Kinde; Amanda Blackford; Siva P Raman; Christopher L Wolfgang; Tyler Tomita; Noushin Niknafs; Christopher Douville; Janine Ptak; Lisa Dobbyn; Peter J Allen; David S Klimstra; Mark A Schattner; C Max Schmidt; Michele Yip-Schneider; Oscar W Cummings; Randall E Brand; Herbert J Zeh; Aatur D Singhi; Aldo Scarpa; Roberto Salvia; Giuseppe Malleo; Giuseppe Zamboni; Massimo Falconi; Jin-Young Jang; Sun-Whe Kim; Wooil Kwon; Seung-Mo Hong; Ki-Byung Song; Song Cheol Kim; Niall Swan; Jean Murphy; Justin Geoghegan; William Brugge; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; Richard Schulick; Barish H Edil; Volkan Adsay; Jorge Paulino; Jeanin van Hooft; Shinichi Yachida; Satoshi Nara; Nobuyoshi Hiraoka; Kenji Yamao; Susuma Hijioka; Schalk van der Merwe; Michael Goggins; Marcia Irene Canto; Nita Ahuja; Kenzo Hirose; Martin Makary; Matthew J Weiss; John Cameron; Meredith Pittman; James R Eshleman; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Rachel Karchin; Ralph H Hruban; Bert Vogelstein; Anne Marie Lennon Journal: Gastroenterology Date: 2015-08-04 Impact factor: 22.682